5-ALA-pretreated | Non-pretreated | P-value | |
---|---|---|---|
Number | 17 | 16 | |
Age (yr) | 64 [47–72] | 71 [44–76] | 0.871 |
Sex | 0.303 | ||
Female | 11 (64.7%) | 7 (43.8%) | |
Male | 6 (35.3%) | 9 (56.2%) | |
BMI (kg/m2) | 22.4 [20.6–24.6] | 22.2 [20.5–24.1] | 0.652 |
Tumor | |||
Recurrence | 7 (41.2%) | 3 (18.8%) | 0.259 |
Pathology | 1.000 | ||
Gliomas | 15 (88.2%) | 14 (87.5%) | |
Lymphoma | 0 (0.0%) | 1 (6.2%) | |
Metastatic tumor | 2 (11.8%) | 1 (6.2%) | |
MRI volume (cm3) | 37.6 [34.5–81.1] | 24.5 [15.1–54.2] | 0.292 |
KPS score | 60 [50–60] | 60 [50–80] | 0.607 |
Comorbidity | 7 (41.2%) | 6 (37.5%) | 1.000 |
Hypertension | 5 (29.4%) | 3 (18.8%) | 0.688 |
Diabetes mellitus | 0 (0.0%) | 1 (6.2%) | 0.485 |
Heart disease | 0 (0.0%) | 1 (6.2%) | 0.485 |
Hyperlipidemia | 3 (17.6%) | 3 (18.8%) | 1.000 |
CKD | 0 (0.0%) | 2 (12.5%) | 0.227 |
Stroke | 0 (0.0%) | 0 (0.0%) | 1.000 |
Laboratory data | |||
TP (g/dL) | 6.7 [6.4–7.0] | 6.8 [6.7–7.2] | 0.481 |
Alb (g/dL) | 3.8 [3.5–4.2] | 4.3 [3.9–4.5] | 0.063 |
AST (IU/L) | 16 [14–18] | 23 [19–27] | 0.008 |
ALT (IU/L) | 15 [12–20] | 18 [12–23] | 0.329 |
Hb (g/dL) | 12.6 [11.3–14.1] | 13.7 [12.7–15.1] | 0.528 |
Antihypertensives | 5 (29.4%) | 2 (12.5%) | 0.398 |
RAS inhibitor | 3 (17.6%) | 1 (6.2%) | 0.601 |
β-Blocker | 0 (0.0%) | 0 (0.0%) | N/A |
Ca antagonist | 2 (11.8%) | 1 (6.2%) | 1.000 |
Intraoperative | |||
Operative time (min) | 211 [161–228] | 144 [126–151] | <0.001 |
SBP <80mmHg | |||
–T4 | 7 (41.2%) | 6 (37.5%) | 1.000 |
–T6 | 6 (35.3%) | 6 (37.5%) | 1.000 |
Vasoactives | 16 (94.1%) | 14 (87.5%) | 0.601 |
Blood loss | 130 [50–350] | 45 [20–127] | 0.024 |
Postoperative | |||
MV | 15 (88.2%) | 9 (56.2%) | 0.057 |
Dopamine | 2 (11.8%) | 1 (6.2%) | 1.000 |
5-ALA-pretreated | Non-pretreated | P-value | |
---|---|---|---|
Number | 26 | 101 | |
Age (yr) | 73 [63–77] | 75 [64–79] | 0.229 |
Sex | 0.436 | ||
Female | 4 (15.4%) | 24 (23.8%) | |
Male | 22 (84.6%) | 77 (76.2%) | |
BMI (kg/m2) | 23.0 [20.8–24.3] | 23.1 [20.7–25.0] | 0.986 |
Tumor | |||
Recurrency | 13 (50.0%) | 43 (42.6%) | 0.515 |
Pathology | 0.277 | ||
Ta | 11 (42.3%) | 37 (36.6%) | |
T1 | 7 (26.9%) | 34 (33.7%) | |
T2 | 0 (0.0%) | 9 (8.9%) | |
CIS | 5 (19.2%) | 8 (7.9%) | |
Others | 3 (11.5%) | 13 (12.9%) | |
Comorbidity | 20 (76.9%) | 75 (74.3%) | 1.000 |
Hypertension | 13 (50.0%) | 54 (53.5%) | 0.827 |
Diabetes mellitus | 9 (34.6%) | 19 (18.8%) | 0.110 |
Heart disease | 6 (23.1%) | 11 (10.9%) | 0.115 |
Hyperlipidemia | 6 (23.1%) | 28 (27.7%) | 0.805 |
CKD | 7 (26.9%) | 32 (31.7%) | 0.812 |
Stroke | 1 (3.8%) | 6 (5.9%) | 1.000 |
Laboratory data | |||
TP (g/dL) | 6.8 [6.7–7.2] | 7.0 [6.7–7.3] | 0.217 |
Alb (g/dL) | 4.2 [3.9–4.2] | 4.1 [3.8–4.3] | 0.629 |
AST (IU/L) | 22 [19–27] | 24 [21–29] | 0.152 |
ALT (IU/L) | 21 [14–28] | 18 [14–25] | 0.749 |
Hb (g/dL) | 14.4 [13.9–15.2] | 13.7 [12.8–14.7] | 0.005 |
Preoperative BTF | 0 (0.0%) | 4 (4.0%) | 0.581 |
Antihypertensives | 13 (50.0%) | 51 (50.5%) | 1.000 |
RAS inhibitor | 9 (34.6%) | 28 (27.7%) | 0.479 |
β-Blocker | 1 (3.8%) | 13 (12.9%) | 0.298 |
Ca antagonist | 7 (26.9%) | 30 (29.7%) | 1.000 |
Postural hypotension | 2 (7.7%) | 0 (0.0%) | 0.041 |
Anesthesia plan | 0.014 | ||
GA | 7 (26.9%) | 8 (7.9%) | |
SA | 19 (73.1%) | 93 (92.1%) | |
Intraoperative | |||
Operative time (min) | 38 [26–55] | 25 [16–33] | 0.002 |
SBP <80mmHg | 10 (40.0%) | 2 (2.0%) | <0.001 |
Vasoactives | 14 (53.8%) | 3 (3.0%) | <0.001 |
Postoperative | |||
THP | 19 (76.0%) | 55 (54.5%) | 0.069 |
Diclofenac | 13 (52.0%) | 33 (32.7%) | 0.103 |
Hematuria | 0.435 | ||
Non-visible | 17 (70.8%) | 58 (57.4%) | |
Faint | 3 (12.5%) | 24 (23.8%) | |
Gross | 4 (16.7%) | 19 (18.8%) |
NeuroSRG | Urological-SRG | P-value | |
---|---|---|---|
Number | 17 | 26 | |
Age | 64 [47–72] | 73 [63–77] | 0.098 |
Sex | 0.002 | ||
Female | 11 (64.7%) | 4 (15.4%) | |
Male | 6 (35.3%) | 22 (84.6%) | |
BMI (kg/m2) | 22.4 [20.6–24.6] | 23.0 [20.8–24.3] | 0.759 |
KPS score | 60 [50–60] | 100 [100–100] | <0.001 |
Tumor | |||
Recurrence | 7 (41.2%) | 13 (50.0%) | 0.756 |
Tumor size | N/A | ||
MRI volume (cm3) | 37.6 [34.5–81.1] | N/A | |
T (TNM classification) | N/A | ||
Ta | 11 (42.3%) | ||
T1 | 7 (26.9%) | ||
T2 | 0 (0.0%) | ||
CIS | 5 (19.2%) | ||
Others | 3 (11.5%) | ||
Comorbidity | 7 (41.2%) | 20 (76.9%) | 0.026 |
Hypertension | 5 (29.4%) | 13 (50.0%) | 0.219 |
Diabetes mellitus | 0 (0.0%) | 9 (34.6%) | 0.007 |
Heart disease | 0 (0.0%) | 6 (23.1%) | 0.066 |
Hyperlipidemia | 3 (17.6%) | 6 (23.1%) | 1.000 |
CKD | 0 (0.0%) | 7 (26.9%) | 0.031 |
Stroke | 0 (0.0%) | 1 (3.8%) | 1.000 |
Antihypertensives | 5 (29.4%) | 13 (50.0%) | 0.219 |
RAS inhibitor | 3 (17.6%) | 9 (34.6%) | 0.306 |
β-Blocker | 0 (0.0%) | 1 (3.8%) | 1.000 |
Ca antagonist | 2 (11.8%) | 7 (26.9%) | 0.281 |
Laboratory data | |||
Alb (g/dL) | 3.8 [3.5–4.2] | 4.2 [3.9–4.2] | 0.021 |
Hb (g/dL) | 12.6 [11.3–14.1] | 14.4 [13.9–15.2] | 0.001 |
SBP <80mmHg (T4) | 7 (41.2%) | 10 (40.0%) | 1.000 |
SBP < 80mmHg | SBP ≥80mmHg | P-value | |
---|---|---|---|
Number | 10 | 15 | |
Age (yr) ≥80 | 1 (10.0%) | 2 (13.3%) | 1.000 |
Sex | 0.626 | ||
Female | 1 (10.0%) | 3 (20.0%) | |
Male | 9 (90.0%) | 12 (80.0%) | |
BMI (kg/m2) ≥25 | 3 (30.0%) | 2 (13.3%) | 0.358 |
Anesthesia | 0.075 | ||
GA | 5 (50.0%) | 2 (13.3%) | |
SA | 5 (50.0%) | 13 (86.7%) | |
Comorbidity | 8 (80.0%) | 11 (73.3%) | 1.000 |
Hypertension | 8 (80.0%) | 4 (26.7%) | 0.015 |
Diabetes mellitus | 4 (40.0%) | 5 (33.3%) | 1.000 |
Heart disease | 3 (30.0%) | 3 (20.0%) | 0.653 |
Hyperlipidemia | 3 (30.0%) | 3 (20.0%) | 0.653 |
CKD | 3 (30.0%) | 4 (26.7%) | 1.000 |
Stroke | 0 (0.0%) | 1 (6.7%) | 1.000 |
Antihypertensives | 8 (80.0%) | 4 (26.7%) | 0.015 |
RAS inhibitor | 4 (40.0%) | 4 (26.7%) | 0.667 |
Ca antagonist | 3 (30.0%) | 4 (26.7%) | 1.000 |
β-Blocker | 1 (10.0%) | 0 (0.0%) | 0.400 |
Pathology | 0.353 | ||
Ta | 3 (30.0%) | 8 (53.3%) | |
T1 | 3 (30.0%) | 4 (26.7%) | |
CIS | 2 (20.0%) | 3 (20.0%) | |
Others | 2 (20.0%) | 0 (0.0%) |